- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT01227668
Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder
Безопасность и эффективность арипипразола при длительном поддерживающем лечении детей с раздражительностью, связанной с аутистическим расстройством
The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo.
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 4
Контакты и местонахождение
Места учебы
-
-
Alabama
-
Dothan, Alabama, Соединенные Штаты, 36303
- Harmonex Neuroscience Research, Inc
-
-
Arizona
-
Phoenix, Arizona, Соединенные Штаты, 85006
- Southwest Autism Research And Resource Center
-
-
California
-
Costa Mesa, California, Соединенные Штаты, 92626
- Clinical Innovations, Inc.
-
Glendale, California, Соединенные Штаты, 91206
- Behavioral Research Specialists, Llc
-
Palo Alto, California, Соединенные Штаты, 94306
- Abbey Neuropsychology Clinic
-
San Francisco, California, Соединенные Штаты, 94143
- Ucsf - Lppi
-
Stanford, California, Соединенные Штаты, 94305
- Stanford University School Of Medicine
-
-
District of Columbia
-
Washington D.C., District of Columbia, Соединенные Штаты, 20010
- Children'S National Medical Center
-
-
Florida
-
Gainesville, Florida, Соединенные Штаты, 32607
- Sarkis Clinical Trials
-
Hialeah, Florida, Соединенные Штаты, 33012
- Palm Springs Research Institute
-
Maitland, Florida, Соединенные Штаты, 32751
- Florida Clinical Research Center, Llc
-
Miami, Florida, Соединенные Штаты, 33155
- Miami Children'S Hospital
-
Tampa, Florida, Соединенные Штаты, 33613
- University Of South Florida
-
-
Georgia
-
Smyrna, Georgia, Соединенные Штаты, 30080
- Institute For Behavioral Medicine, Llc
-
-
Idaho
-
Coeur d'Alene, Idaho, Соединенные Штаты, 83814
- Kootenai Behavioral Health Center
-
-
Kentucky
-
Louisville, Kentucky, Соединенные Штаты, 40202
- Kosair Charities Pediatric Clinical Research Unit
-
-
Louisiana
-
Shreveport, Louisiana, Соединенные Штаты, 71103
- Lsu Health Sciences Center
-
-
Massachusetts
-
Newton, Massachusetts, Соединенные Штаты, 02459
- Neurocare, Inc.
-
-
Michigan
-
Bloomfield Hills, Michigan, Соединенные Штаты, 48302
- Neurobehavioral Medicine Group
-
-
Nevada
-
Las Vegas, Nevada, Соединенные Штаты, 89128
- Center For Psychiatry And Behavioral Medicine, Inc
-
-
New Jersey
-
Gibbsboro, New Jersey, Соединенные Штаты, 08026
- Clinical Research Center Of New Jersey
-
Toms River, New Jersey, Соединенные Штаты, 08755
- Children'S Specialized Hosp
-
-
New York
-
Stony Brook, New York, Соединенные Штаты, 11794
- Stony Brook University School Of Medicine
-
-
North Carolina
-
Chapel Hill, North Carolina, Соединенные Штаты, 27517
- Unc Chapel Hill
-
-
Ohio
-
Cleveland, Ohio, Соединенные Штаты, 44106
- University Hospitals Case Medical Center
-
Cleveland, Ohio, Соединенные Штаты, 44104
- Cleveland Clinic
-
Columbus, Ohio, Соединенные Штаты, 43210
- The Ohio State University Nisonger Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73116
- Cutting Edge Research Group
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73117
- Ou Physician'S Child Study Center
-
Tulsa, Oklahoma, Соединенные Штаты, 74104
- Tulsa Clinical Research, Llc
-
-
Oregon
-
Gresham, Oregon, Соединенные Штаты, 97030
- Cyn3rgy Research
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19124
- Drexel University College Of Medicine
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15203
- Western Psychiatric Institute And Clinic
-
-
Tennessee
-
Kingsport, Tennessee, Соединенные Штаты, 37660
- Holston Medical Group
-
-
Texas
-
DeSoto, Texas, Соединенные Штаты, 75115
- Insite Clinical Research
-
-
Utah
-
Clinton, Utah, Соединенные Штаты, 84015
- Ericksen Research And Development
-
-
Virginia
-
Norfolk, Virginia, Соединенные Штаты, 23510
- Childrens Specialty Gr., Pllc
-
Richmond, Virginia, Соединенные Штаты, 23298
- Virginia Treatment Center For Children
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Key Inclusion Criteria:
- Male or female children or adolescents, 6 to 17 years of age, inclusive, at the time of the baseline visit
- Meets current diagnostic criteria of the Diagnostic and Statistical Manual-of Mental Disorders IV-Text Revised for autistic disorder and displays behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. Diagnosis of autistic disorder will be confirmed by the Autism Diagnostic Interview-Revised.
- Participant or designated guardian or caregiver is able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the investigator.
- Demonstrates behaviors such as tantrums, aggression, or self-injury or a combination of these problems
- An Aberrant Behavior Checklist Irritability subscale score ≥18 AND a Clinical Global Impressions Severity score ≥4 at the Screening and Baseline Visits.
- Mental age of at least 24 months
Key Exclusion Criteria:
- Treatment resistant to neuroleptic medication, based on lack of therapeutic response to 2 different neuroleptics after treatment for at least 3 weeks each.
- Previous treatment with aripiprazole for at least 3 weeks duration at an adequate daily dose, without demonstrating a clinically meaningful response.
- Lifetime diagnosis of bipolar disorder, psychosis, or schizophrenia, or a current diagnosis of major depressive disorder
- Diagnosis of Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Syndrome, Rett's Syndrome, childhood disintegrative disorder, or Fragile X Syndrome
- History of neuroleptic malignant syndrome
- At significant risk for suicide based on history or routine psychiatric status examination
- A seizure within the past year
- History of severe head trauma or stroke
- History or current evidence of any unstable medical conditions that would expose the patient to undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial
- Weight lower than 15 kg
- Known allergy or hypersensitivity to aripiprazole or other dihidrocarbostyrils
- History of a clinically significant low white blood cell count or a drug-induced leukopenia/neutropenia
- Any other medically significant abnormal laboratory test or vital sign result or electrocardiogram finding
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Плацебо Компаратор: Плацебо
|
Tablets, oral, 0 mg, once daily, 16 weeks |
|
Экспериментальный: Арипипразол
|
Tablets, oral, 2-15 mg, once daily, 13-42 weeks
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percentage of Patients Relapsing by Week 16
Временное ограничение: From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment
|
Time of relapse=date when patient meets relapse criteria. There are 4 definitions for relapse: 1. Patient meets the following criteria for 2 consecutive visits: (a) Aberrant Behavior Checklist Irritability score ≥25% than score at end of Phase 1 AND (b) Clinical Global Impression Improvement scale rating of 'Much Worse' or 'Very Much Worse' relative to rating at end of Phase 1. If relapse criteria met at 1 visit, 2nd visit should occur in about 1 week to reevaluate whether relapse criteria are still met. 2. Patient discontinues for "Lost to Follow-up" after a visit in which he or she met Definition 1 criteria (a&b). 3. Patient begins a prohibited drug (whether a study investigator or outside source prescribed) to treat worsening symptoms of irritability of autistic disorder after a visit where patient met Definition 1 criteria (a&b). 4. Patient discontinues due to hospitalization for worsening symptoms of irritability or due to lack of efficacy based on investigator's assessment. |
From end of Phase 1 (Date of randomization) to Week 16 of Phase 2 and end of treatment
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Adjusted Mean Change From Baseline to Week 16 on the Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score (Last Observation Carried Forward [LOCF])
Временное ограничение: From Baseline (end of Phase 1) to Week 16 of Phase 2
|
ABC is an informant-based checklist used to assess and classify problem behaviors of children and adolescents with mental retardation. The 58 items are rated on a 4-point scale (0=not at all a problem to 3=the problem is severe in degree), and resolve into 5 subscales: 1) irritability, agitation; 2) lethargy, social withdrawal; 3) stereotypic behavior; 4) hyperactivity, noncompliance; and 5) inappropriate speech. The ABC can be completed by parents, special educators, psychologists, direct caregivers, nurses, and others knowing the participant. Psychometric assessment of the ABC indicates that its subscales have high internal consistency, adequate reliability, and established validity. The ABC-I Subscale Score ranges from 0 to 45, with a negative change in score signifying improvement. LOCF data set includes data recorded at a given visit or, if no observation was recorded at that visit, data carried forward from the prior visit. chg=change; BL=baseline; APR=aripiprazole; vs=versus. |
From Baseline (end of Phase 1) to Week 16 of Phase 2
|
|
Change From Baseline in Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 16 (Last Observation Carried Forward [LOCF])
Временное ограничение: From Baseline (end of Phase 1) to Week 16 of Phase 2
|
CG-I rating scale permits global evaluation of patient's improvement over time. At baseline (BL), CGI Severity of Illness assessment is performed, in which the clinician rates severity of patient's condition on a 7-point scale ranging from 1=no symptoms to 7=very severe symptoms. Higher total score=worse symptoms. At subsequent visits, clinician assesses patient's improvement relative to symptoms at baseline on CGI-I 7-point scale ranging from 1=very much improved to 7=very much worse. Since the drug targets irritability symptoms, the CGI focuses on severity of irritability secondary to autistic disorder. Lower score=more improved symptoms. LOCF data set includes data recorded at a given visit or, if nothing recorded, data areccarried forward from the prior visit. For secondary endpoints (endpt), hierarchical testing was used to keep overall experiment-wise type I error rate to <=0.05. diff=difference; IS=irritability scale; PA=primary analysis; signif=significance/significantly. |
From Baseline (end of Phase 1) to Week 16 of Phase 2
|
|
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation During Phase 1
Временное ограничение: Up to 26 weeks
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. |
Up to 26 weeks
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Treatment-related AEs During Phase 2
Временное ограничение: Weekly from Weeks 1 through 16 (end of treatment) of Phase 2
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. |
Weekly from Weeks 1 through 16 (end of treatment) of Phase 2
|
Соавторы и исследователи
Публикации и полезные ссылки
Общие публикации
- Findling RL, Mankoski R, Timko K, Lears K, McCartney T, McQuade RD, Eudicone JM, Amatniek J, Marcus RN, Sheehan JJ. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry. 2014 Jan;75(1):22-30. doi: 10.4088/jcp.13m08500.
- Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оцененный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- CN138-603
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .